Navigation Links
The Lancet Publishes Data from Protege, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
Date:6/28/2011

1-year results from a randomized, placebo-controlled trial," by Sherry, et al.(1) and provides the results of per protocol as well as exploratory, post hoc analyses.  The findings suggest that "future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in beta-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children."

The article indicates that teplizumab treatment may preserve beta cell function as measured by C-peptide, allowing less insulin use to achieve the same glycemic control as patients receiving placebo. A greater proportion of patients in the teplizumab groups were able to discontinue or use very low doses of insulin compared to the placebo group.  A reduced insulin requirement while maintaining glycemic control appears to support teplizumab having a biological effect.

In the safety analyses, the proportion of patients who had adverse events and serious adverse events was similar across the four study groups.  Rash was the most common clinical adverse event reported more frequently with teplizumab than placebo. Mild cytokine release syndrome was infrequent but greater in treatment groups compared to placebo. The safety profile was characterized by transient increases in some liver function test results and transient decreases in white cells that prevent infections. However, no increase in overall infections was seen.

"We are very pleased to have teplizumab Phase 3 data published in this prestigious journal," stated Dr. Scott Koenig, President and CEO of MacroGenics.  "Although the Protege study missed its primary endpoint, the data appear to indicate that teplizumab has a desired biological effect in certain subpopulations with a potentially meaningful therapeutic benefit for patients with recent-onset type 1 diabetes.  These groups in
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
4. CHAMPION Study Published in The Lancet
5. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
6. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
7. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
8. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
9. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
10. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
11. Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... BOCA RATON, Fla. , Dec. 19, 2014 /PRNewswire/ ... entered into a multi-product agreement with MSN Laboratories Pvt. ... Breckenridge and MSN expect to commercialize several new ANDAs. ... manufacture, and supply the products exclusively to Breckenridge for ... the products under its label.  Breckenridge and MSN have ...
(Date:12/19/2014)... HILL, N.C. , Dec. 19, 2014 /PRNewswire/ ... to optimize a product,s web presence to reflect ... Brand websites, in particular, must meet the needs ... regulations and culture. According to ... more than half of the participating companies averaged ...
(Date:12/19/2014)... 2014  Monarch America Inc. (OTCQB: CANK) ("Monarch America" ... to provide this review of the Company,s recent achievements ... "Over this past year, we achieved many of ... proud to say that Monarch America is in a ... ever been," stated Eric Hagen , CEO of ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Building a Best-in-Class Pharma Global Brand Website 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3
... 14, 2011  Heska Corporation (NASDAQ: HSKA ; ... and specialty products to veterinarians, announced today the intent ... expertise in blood-related disorders.  The parties are to explore ... cell-based therapeutics, for use in the veterinary market.      ...
... Group, Inc. (OTCMARKETS: UYMG) "UNITY" (or the "Company"), and its ... it has sold its initial PZ Uno Tablet press to ... the company is not able to disclose the name of ... tablet press would be used for a research and development ...
Cached Medicine Technology:Heska Announces Exploration of New Technologies Through Strategic Collaboration with Entegrion, Inc. 2Heska Announces Exploration of New Technologies Through Strategic Collaboration with Entegrion, Inc. 3Unity Management Group, Inc. Announces Its Initial Sale of the PZ UNO Tablet Press to a Major Pharmaceutical Company for $500,000 2
(Date:12/20/2014)... December 20, 2014 Weddingshe.com has recently ... launched a site-wide promotion of special occasion dresses for ... popular supplier of special occasion dresses for global women. ... with big discounts, up to 80% off. Among the ... Sequins Short Sweet 16 Dress) is very popular. What’s ...
(Date:12/20/2014)... December 20, 2014 DePuy Pinnacle ... metal-on-metal version of the artificial hip system was ... and federal courts, Bernstein Liebhard LLP reports. According ... County Superior Court on December 2nd, counsel in ... deposition of plaintiffs on November 19, 2014, with ...
(Date:12/20/2014)... 20, 2014 Recently, VogueQueen.com, a leading ... VogueQueen Big Sale Online for 2015. Great discounts ... new and old consumers can get a discount, up ... the company’s website before January 30, 2015. , VogueQueen.com ... and launched a prom dress promotion. Many customers worldwide ...
(Date:12/20/2014)... York (PRWEB) December 20, 2014 ... to move forward in U.S. courts, Bernstein Liebhard ... which suggests that children treated with the medication ... linked to breast development and lactation. The study, ... 34 children and adolescents who began treatment with ...
(Date:12/20/2014)... Recently, AngelWeddingDress.com has introduced its special offer ... coming Christmas. In the promotion, all buyers worldwide can ... have something special for the women who are looking ... our new collections of 2015 dresses have been unveiled ... greatly discounted prices. Visit our website now before they ...
Breaking Medicine News(10 mins):Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2
... March 31 /PRNewswire-FirstCall/ - Response Biomedical,Corporation (TSX: RBM, ... $4,084,116 and a net loss of $13,901,041 or ... 2007. Additionally, the Company announced,that as of December ... working,capital. For a further discussion of the Company,s ...
... /Xinhua-PRNewswire/ -- China Medicine,Corporation (OTC Bulletin Board: ... distributor and developer of prescription and over-the-counter,pharmaceuticals, ... medical devices, and medical formulations in the ... at the upcoming Brean Murray,Carret & Co. ...
... to Benefit Prevention, Control Efforts in Every,County, HARRISBURG, ... from an aggressive effort to monitor and control,mosquitoes this ... a $5.3 million investment that will help fight to ... the past several years to protect the,public,s health by ...
... March 31 CNS Response,Inc. (OTC Bulletin ... its,agreement to roll out referenced-EEG(R) (rEEG(R)) availability ... (MBHO). This,agreement enables psychiatrists under the management ... medication guidance to treat their most,therapy-challenged patients ...
... LAKES, NJ, STOCKHOLM, Sweden, March 31 /PRNewswire-FirstCall/,-- ... ) today announced a collaboration,with Sweden,s government-operated ... the first automated electronic prescription-review system,to improve ... and the,country,s health care system., Under ...
... congratulated,Third Wave Technologies Inc., Madison, Wis., on the ... CLIA-certified SeqWright is,a leader in the field of ... validated the InPlex(TM) CF test by,demonstrating it had ... a critical role in the test gaining FDA ...
Cached Medicine News:Health News:Response Biomedical Corporation Reports 2007 Financial Results 2Health News:Response Biomedical Corporation Reports 2007 Financial Results 3Health News:Response Biomedical Corporation Reports 2007 Financial Results 4Health News:Response Biomedical Corporation Reports 2007 Financial Results 5Health News:China Medicine Corporation to Present at Brean Murray Carret & Co. Mainland China Investor Tour 2Health News:Governor Rendell Proposes County Grants to Combat West Nile Virus, Protect Public Health 2Health News:Governor Rendell Proposes County Grants to Combat West Nile Virus, Protect Public Health 3Health News:Governor Rendell Proposes County Grants to Combat West Nile Virus, Protect Public Health 4Health News:Governor Rendell Proposes County Grants to Combat West Nile Virus, Protect Public Health 5Health News:CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization 2Health News:CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization 3Health News:CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization 4Health News:Medco Partners to Develop Patient-Safety System for Prescription Drugs in Sweden 2Health News:Medco Partners to Develop Patient-Safety System for Prescription Drugs in Sweden 3Health News:SeqWright's Partnership With Third Wave Contributes to FDA Success 2
... a cruciate sparing version which provides ... both resurfacing and inset patellas. Precision ... and fit with tibial articular surface ... cutting guide peg locations provide easy ...
The Balanced Knee System provides instrumentation designed to achieve proper tissue balancing and alignment with user-friendly instrumentation that provides reproducible results....
Advance Posterior Stabilized Total Knee systems improves patellofemoral kinematics, reduces wear rate potential, increases resistance to posterior tibial dislocation, achieves at least 120o flexion i...
... The Duracon tibial inserts have radiused ... advanced 4-axis machining, maximizing conformity of ... condyles of the femoral component. The ... the Duracon system, and accommodates the ...
Medicine Products: